View Filing Data

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Sep. 30, 2015	Apr. 26, 2016
Document Type	10-Q
Amendment Flag	true
Amendment Description	Helius Medical Technologies, Inc. (the “Company”) is filing this amendment on Form 10-Q/A (this “Second Amendment”) to amend its Quarterly Report on Form 10-Q for the three and six months ended September 30, 2015, as filed on November 16, 2015 (the “Original Filing”) and previously amended on January 11, 2016 (the “First Amended Filing”), to restate its interim condensed consolidated financial statements as of and for the three and six months ended September 30, 2015, as a result of an error in the classification of warrants issued in private placements conducted in April, June, and July 2015. The Company previously recorded the issuance of warrants in private placements conducted in April, June, and July 2015 as equity instruments instead of liabilities. The warrant exercise prices are denominated in U.S. dollars whereas the functional currency of the Company is the Canadian dollar; as such, the settlement of the warrants fails the fixed for fixed criteria of ASC 815 and they are required to be recorded as a liability at their fair value on inception. The warrant liability is required to be re-measured at its fair value on each reporting date with the changes in fair value recorded in the Company’s Statement of Comprehensive Loss. See Note 12 “Second Restatement of Previously Issued Financial Statements” to the Company’s restated interim condensed consolidated financial statements.The Company previously filed the First Amended Filing to restate its interim condensed consolidated financial statements as of and for the three months ended June 30, 2015, as a result of the Company not previously re-measuring the fair value of stock options awarded to non-employees that had not yet vested. See Note 11 “Correction of an Error in Previously Issued Financial Statements” to the Company’s restated interim condensed consolidated financial statements. In connection with the Original Filing and the First Amended Filing, under the direction of our Chief Executive Officer and our Chief Financial Officer, our management evaluated our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act, and concluded that our disclosure controls and procedures were ineffective as of September 30, 2015. Subsequently, the Company’s management has determined that the improper design of controls with respect to the calculation of the fair value of the Company’s share based compensation and warrants was a deficiency in its internal control over financial reporting resulting from the material weaknesses identified at September 30, 2015.Except as required to reflect the effects of the corrections for the items above, no additional modifications or updates have been made to the Original Filing and are set forth in this Second Amendment. Information not affected by these corrections remains unchanged and reflects the disclosure made at the time of the First Amendment. This Second Amendment does not describe other events occurring after the Original Filing or the First Amendment, including exhibits, or modify or update those disclosures affected by subsequent events. This Amendment should be read in conjunction with the Company’s filings made with the Securities and Exchange Commission subsequent to the filing of the Original Filing and the First Amendment, as information in such reports and documents may update or supersede certain information contained in this Second Amendment.The certifications of the Company’s Chief Executive Officer and Chief Financial Officer are attached to this Second Amendment as Exhibits 31.1, 31.2, and 32.1 respectively.
Document Period End Date	Sep. 30, 2015
Trading Symbol	hsm
Entity Registrant Name	HELIUS MEDICAL TECHNOLOGIES, INC.
Entity Central Index Key	0001610853
Current Fiscal Year End Date	--03-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		81,408,209
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well Known Seasoned Issuer	No
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q2

Interim Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2015	Mar. 31, 2015
Current assets
Cash and cash equivalents	$ 192,256	$ 418,893
Short-term investment	0	378,000
Receivables	115,672	8,833
Prepaid expenses	411,180	410,621
Total current assets	719,108	1,216,347
TOTAL ASSETS	719,108	1,216,347
Current liabilities
Accounts payable and accrued liabilities	1,140,904	1,197,804
Promissory note payable	200,000	0
Deferred expense reimbursement	120,847	0
Total current liabilities	1,461,751	1,197,804
Derivative liability	397,763	1,581,444
TOTAL LIABILITIES	1,859,514	2,779,248
CAPITAL DEFICIT
Common stock (Unlimited Class A common shares authorized); (64,524,320 shares outstanding at September 30, 2015 and 63,104,788 shares outstanding at March 31, 2015)	18,576,905	16,358,093
Additional paid-in capital	1,823,730	2,434,552
Shares to be issued	0	39,545
Accumulated other comprehensive income	(1,498,533)	(971,640)
Accumulated deficit	(20,042,508)	(19,423,451)
TOTAL CAPITAL DEFICIT	(1,140,406)	(1,562,901)
TOTAL LIABILITIES & CAPITAL DEFICIT	$ 719,108	$ 1,216,347

Interim Condensed Consolidated Balance Sheets (Parenthetical) - shares	Sep. 30, 2015	Mar. 31, 2015
Common Stock, Shares Authorized
Common Stock, Shares, Outstanding	64,524,320	63,104,788

Interim Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Operating Expenses
Advertising, marketing & investor relations	$ 240,368	$ 357,956	$ 548,581	$ 404,182
Audit & accounting	23,738	30,836	104,200	41,481
Consulting fees	(24,992)	215,030	80,995	266,353
Insurance	30,465	22,287	60,004	29,773
Legal fees	205,310	344,491	499,046	564,425
Meals & travel	31,803	77,611	127,670	107,052
Office & general	26,725	83,747	52,764	118,296
Research & development	1,531	1,254,186	1,372,457	2,004,540
Transfer agent & regulatory	16,373	43,713	48,952	58,973
Wages and salaries	174,351	333,645	666,778	552,256
Loss from operations	(725,672)	(2,763,502)	(3,561,447)	(4,147,331)
Other items
Interest expense	0	0	0	(176,488)
Interest and other income	27,801	7,811	27,748	10,621
Change in fair value of derivative liability	1,894,305	(594,254)	2,407,089	(594,254)
Foreign exchange gain (loss)	588,978	(406,182)	507,553	(412,628)
Total Other Income (Loss)	2,511,084	(992,625)	2,942,390	(1,172,749)
Net income (loss) for the period	1,785,412	(3,756,127)	(619,057)	(5,320,080)
Other comprehensive income
Translation adjustments	(567,519)	206,786	(526,893)	312,845
Comprehensive income (loss) for the period	$ 1,217,893	$ (3,549,341)	$ (1,145,950)	$ (5,007,235)

Interim Condensed Consolidated Statements of Capital Equity (Deficit) - 6 months ended Sep. 30, 2015 - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Shares to be Issued [Member]	Accumulated Deficit [Member]	Accumulated other comprehensive income (loss)[Member]	Total
Beginning Balance at Mar. 31, 2015	$ 16,358,093	$ 2,434,552	$ (19,423,451)	$ 39,545	$ (971,640)	$ (1,562,901)
Beginning Balance (Shares) at Mar. 31, 2015	63,104,788
Exercise of finders' warrants	$ 11,926					11,926
Exercise of finders' warrants (Shares)	14,400
Issuance of common stock for private placement	$ 1,465,524					1,465,524
Issuance of common stock for private placement (Shares)	849,273
Issuance of common stock for private placement 2	$ 585,702			$ (39,545)		546,157
Issuance of common stock for private placement 2 (Shares)	335,463
Issuance of common stock for private placement 3	$ 233,806					233,806
Issuance of common stock for private placement 3 (Shares)	125,756
Stock option exercise	$ 42,500					42,500
Stock option exercise (Shares)	94,640
Fair value of options exercised	$ 20,454	(20,454)
Share issuance cost	(141,100)					(141,100)
Stock-based compensation on 2,570,000 options granted		(146,717)				(146,717)
Stock-based compensation on 400,000 options granted		198,151				198,151
Stock-based compensation on 100,000 options granted 1		21,644				21,644
Stock-based compensation on 100,000 options granted 2		21,021				21,021
Stock-based compensation on 50,000 options granted		6,418				6,418
Fair value of non-employee vested options reallocated to derivative liability		(690,885)				(690,885)
Net loss for the period			(619,057)			(619,057)
Translation adjustments					(526,893)	(526,893)
Ending Balance at Sep. 30, 2015	$ 18,576,905	$ 1,823,730	$ (20,042,508)		$ (1,498,533)	$ (1,140,406)
Ending Balance (Shares) at Sep. 30, 2015	64,524,320

Interim Condensed Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities
Net loss for the period	$ (619,057)	$ (5,320,080)
Items not involving cash:
Change in fair value of derivative liability	(2,407,089)	594,254
Stock-based compensation	100,518	937,397
Accretion	0	176,488
Changes in non-cash working capital items:
Receivables	(110,329)	(693)
Deferred expense reimbursement	120,847	0
Prepaid expenses	(1,736)	(84,459)
Accounts payable and accrued liabilities	(47,405)	937,740
Foreign exchange remeasurement	(429,494)	0
Net cash used in operating activities	(3,393,745)	(2,759,353)
Cash flows from investing activities
Short term investment	378,000	0
Cash acquired on recapitalization	0	23,904
Proceeds from bridge loan	0	150,000
Net cash provided by investing activities	378,000	173,904
Cash flows from financing activities
Proceeds from the issuance of shares	2,299,913	6,616,051
Proceeds from the issuance of warrants	532,523	0
Share issuance cost	(141,100)	0
Proceeds from issuance of promissory note	200,000	0
Proceeds from the issuance of convertible debt	0	633,195
Net cash provided by financing activities	2,891,336	7,249,246
Effect of foreign exchange rate changes on cash	(102,228)	320,261
Change in cash for the period	(226,637)	4,984,058
Cash, beginning of the period	418,893	15,968
Cash, end of the period	192,256	5,000,026
Supplemental cash flow information
Interest paid in cash	0	11,144
Income taxes paid in cash	$ 0	$ 0

BASIS OF PRESENTATION

6 Months Ended

Sep. 30, 2015

BASIS OF PRESENTATION [Text Block]

1. BASIS OF PRESENTATION

The accompanying unaudited condensed financial statements of Helius Medical Technologies Inc. (the “Company”) have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, they should be read in conjunction with the audited consolidated financial statements and notes thereto for the fiscal year ended March 31, 2015 included in the Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on June 29, 2015. The unaudited condensed consolidated interim financial statements contain all normal recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the consolidated financial position of the Company at September 30, 2015, and the consolidated results of operations for the three and six months ended September 30, 2015, and consolidated statements of cash flows for the three months ended September 30, 2015. All intercompany accounts and transactions have been eliminated. It should be understood that accounting measures at interim dates inherently involve greater reliance on estimates than at year end. The results of operations for the three and six months ended September 30, 2015 are not necessarily indicative of the results to be expected for the full year or any future interim periods.

SIGNIFICANT ACCOUNTING POLICIES

6 Months Ended

Sep. 30, 2015

SIGNIFICANT ACCOUNTING POLICIES [Text Block]

2. SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation and Liquidity

The Company has incurred a net loss of $619,057 for the six months ended September 30, 2015 and, as of September 30, 2015, the Company has an accumulated deficit of $20,042,508 (March 31, 2015 - $19,423,451). Until the Company generates a level of revenue to support its cost structure, the Company expects to continue to incur substantial operating losses and net cash outflows. While the Company had cash and cash equivalents of $192,256 as of September 30, 2015 (March 31, 2015 - $418,893), management does not believe these resources will be sufficient to meet the Company’s operating and capital needs for the ensuing fiscal year.

The Company intends to fund ongoing activities by utilizing current cash and cash equivalents and by raising additional capital through equity or debt financings. There can be no assurance that the Company will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to the Company. If the Company is unable to raise sufficient additional capital, the Company may be compelled to reduce the scope of its operations and planned capital expenditure or sell certain assets, including intellectual property assets. This material uncertainty gives rise to substantial doubt about the Company’s ability to continue as a going concern.

Fair Value of Financial Assets and Liabilities

The Company’s financial instruments consist primarily of cash and cash equivalents and accounts payable and accrued liabilities. The book values of these instruments approximate their fair values due to the immediate or short-term nature of those instruments.

ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value;

Level 1 – Quoted prices in active markets for identical assets or liabilities;

Level 2 – Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable; and

Level 3 – Unobservable inputs that are supported by little or no market activity, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.

Cash and cash equivalents and short-term investment are measured using Level 1 inputs.

The Company had certain Level 3 liabilities required to be recorded at fair value on a recurring basis in accordance with US GAAP as at September 30, 2015. As at September 30, 2015, the Company’s Level 3 liabilities consisted of the grant of share Purchase options to non-employees. The resulting Level 3 liabilities have no active market and are required to be measured at their fair value each reporting period based on information that is unobservable.

A summary of the Company’s Level 3 liabilities for the periods ended September 30, 2015 and 2014 are as follows:

Non-Employee Options

	Six months ended		Six months ended
	Sept 30, 2015		Sept 30, 2014
	$		$
Beginning fair value	1,581,444		-
Issuance of non-employee options	-		121,344
Reallocation of vested non-employee options	690,885		7,419
Change in fair value	(1,910,420	)	594,254
Ending fair value of non-employee options	361,909		723,017

Warrants

Beginning fair value	-		-
Issuance of warrants	532,523		-
Change in fair value	(496,669	)	-
Ending fair value of warrants	35,854		-
Ending fair value of Level 3 liability	397,763		-

Certain assets and liabilities are measured at fair value on a nonrecurring basis; that is, the instruments are not measured at fair value on an ongoing basis but are subject to fair value adjustments only in certain circumstances (for example, when there is evidence of impairment). There were no assets or liabilities measured at fair value on a non-recurring basis during the periods ended September 30, 2015 and September 30, 2014.

Basic and Diluted Income (Loss) per Share

Earnings or loss per share (“EPS”) is computed by dividing net income (loss) available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted EPS is computed by dividing net income (loss) by the weighted-average of all potentially dilutive shares of common stock that were outstanding during the periods presented. The number of shares potentially issuable at September 30, 2015 upon the exercise or conversion of share purchase warrants, share purchase options and conversion of convertible debentures totaled 5,877,500. The number of shares potentially issuable at June 30, 2014 upon exercise or conversion of share purchase warrants and share purchase options and the conversion of convertible debentures totaled 9,130,000.

The treasury stock method is used in calculating diluted EPS for potentially dilutive stock options and share purchase warrants, which assumes that any proceeds received from the exercise of in-the-money stock options and share purchase warrants, would be used to purchase common shares at the average market price for the period.

EPS for convertible debt is calculated under the “if-converted” method. Under the if converted method, EPS is calculated as the more dilutive of EPS (i) including all interest (both cash interest and non-cash discount amortization) and excluding all shares underlying the Notes or; (ii) excluding all interest and costs directly related to the convertible debt (both cash interest and non-cash discount amortization) and including all shares underlying the convertible debt.

The basic and diluted earnings per share for the three and six months ended September 30, 2015 and 2014 were calculated as follows:

		Three months ended					Six months ended
		September 30, 2015		September 30, 2014			September 30, 2015			September 30, 2014
Basic
Numerator
Net income (loss)	$	1,785,412	$	(3,756,127	)	$	(619,057	)	$	(5,320,080	)
Denominator
Weighted average common shares outstanding		64,408,500		63,104,788			64,055,508			51,025,119

Basic net income (loss) per share	$	0.03	$	(0.06	)	$	(0.01	)	$	(0.10	)

Diluted
Numerator
Net income (loss) for diluted income per share	$	1,785,412	$	(3,756,127	)	$	(619,057	)	$	(5,320,080	)
Denominator
Weighted average common shares outstanding		64,408,500		63,104,788			64,055,508			51,025,119
Potential share
issuances
Common share options		2,135,104		2,855,914			2,652,859			2,814,267

Common share warrants		2,577,769		5,031,974			4,483,136			5,002,389
Weighted average number of common shares outstanding used in computing diluted earnings per share		66,543,604		65,960,702			71,191,503			58,841,775

Diluted earnings per share	$	0.03	$	(0.06	)	$	(0.01	)	$	(0.10	)

Recent Accounting Pronouncements

In April 2015, the FASB issued Accounting Standards Update No. 2015-03 Interest – Imputation of Interest (Subtopic 835 - 30). This guidance is to simplify the presentation of debt issuance costs by recognizing a debt liability in the balance sheet as a direct deduction from that debt liability consistent with the presentation of a debt discount. The amendments in this Update are effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. The Company is currently evaluating the impact of adoption of this new accounting pronouncement on its financial statements.

CONVERTIBLE DEBENTURE

6 Months Ended

Sep. 30, 2015

CONVERTIBLE DEBENTURE [Text Block]

3. CONVERTIBLE DEBENTURE

On February 19, 2014, the Company entered into a securities purchase agreement where the Company agreed to sell and issue a note with annual simple interest at 8% (the “Debenture”). A total of $1,000,100 in principal had been received.

On June 13, 2014, the Debenture matured on the closing of the Company’s qualified financing. Upon completion of the qualified financing, the Debenture automatically converted into equity securities of the Company at a price per share equal to 85% of the price per share of the qualified financing. The conversion option of the Debenture was accounted for as a contingent beneficial conversion feature valued at $176,488 which was recorded as interest expense in the Statement of Comprehensive Loss on settlement of the contingency.

PROMISSORY NOTE

6 Months Ended

Sep. 30, 2015

PROMISSORY NOTE [Text Block]

4. PROMISSORY NOTE

On August 25, 2015, the Company received $200,000 in exchange for the issuance of a promissory note. The promissory note was to be repaid six months from the date of issuance with interest at the rate of 6% per annum. In addition, the lender was entitled to receive 30,000 common shares of the Company on the date of the promissory note and 30,000 common every three months thereafter as long as the principal of the loan remained outstanding.

On October 28, 2015, the Company repaid the loan in its entirety and issued 30,000 common shares that were owed the lender in accordance with the terms of the promissory note.

DEFERRED EXPENSE REIMBURSEMENT

6 Months Ended

Sep. 30, 2015

DEFERRED EXPENSE REIMBURSEMENT [Text Block]

5. DEFERRED EXPENSE REIMBURSEMENT

During the six months ended September 31, 2015, pursuant to the sole-source cost sharing contract executed with the U.S. Army Medical Research and Materiel Command, the Company received a total of $1,037,089 in respect of expenses reimbursed for registrational trial (‘the trial”) investigating the safety and effectiveness of the portable neuromodulation stimulator for mild to moderate traumatic brain injury. Upon receipt, the Company recorded these funds as a deferred expense reimbursement to be applied against charges incurred by the Company as the trial progresses. As of September 30, 2015, the Company had incurred costs of $916,972 on the trial with the remaining $120,847 applied subsequent to September 30, 2015.

COMMON STOCK

6 Months Ended

Sep. 30, 2015

COMMON STOCK [Text Block]

6. COMMON STOCK

Authorized:

Unlimited Class A common shares without par value.

Each Class A common share is entitled to have the right to vote at any shareholder meeting on the basis of one vote per share. Each Class A share held entitles the holder to receive dividends as declared by the directors. In the event of the liquidation, dissolution or winding-up of the Company other distribution of assets of the Company among its shareholders for the purposes of winding-up its affairs or upon a reduction of capital the holders of the Class A common shares shall, share equally, share for share, in the remaining assets and property of the Company.

Class B common shares and Class A preferred shares were deleted from the list of classes of shares the Company is authorized to issue by way of amendment to the Company’s articles effective June 12, 2014.

The Company is subject to a stockholders agreement, which places certain restrictions on the Company’s stock and its stockholders. These restrictions include approvals prior to sale or transfer of stock, a right of first refusal to purchase stock held by the Company and a secondary right of refusal to stockholders, right of co-sale whereby certain stockholders may be enabled to participate in a sale of other stockholders to obtain the same price, term and conditions on a pro-rata basis, rights of first offer of new security issuances to current stockholders on a pro-rata basis and certain other restrictions.

On April 30, 2015 the Company closed a non-brokered private placement (the “First Financing”) raising gross proceeds of $1,825,937 by the issuance of 849,273 units (each a “First Financing Unit”) at a price of $2.15 per First Financing Unit. Each First Financing Unit consists of one (1) common share and one half of one (1/2) common share purchase warrant (each a “First Financing Warrant”). Each whole First Financing Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of $3.00 per share for a period of thirty-six (36) months from the closing date of the Financing. The Company paid a cash finder’s fee of $84,074 in connection with this First Financing, as well as 27,396 finder’s warrants (the “First Financing Finder’s Warrants”). Each First Financing Finder’s Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of $3.00 per share for a period of thirty-six (36) months from the closing date of the First Financing.

On June 26, 2015 the Company closed a non-brokered private placement (the “Second Financing”) raising gross proceeds of $721,243 by the issuance of 335,463 units (each a “Second Financing Unit”) at a price of $2.15 per Second Financing Unit. Each Second Financing Unit consists of one (1) common share and one half of one (1/2) common share purchase warrant (each a “Second Financing Warrant”). Each whole Second Financing Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of $3.00 per share for a period of thirty-six (36) months from the closing date of the Second Financing. The Company paid a cash finder’s fee of $40,803 in connection with this Second Financing, as well as 18,978 finder’s warrants (the “Second Financing Finder’s Warrants”). Each Second Financing Finder’s Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of $2.15 per share for a period of sixty (60) months from the closing date of the Second Financing.

On July 17, 2015 the Company closed a non-brokered private placement (the “Third Financing”) raising gross proceeds of $270,375 by the issuance of 125,756 units (each a “Third Financing Unit”) at a price of $2.15 per Third Financing Unit. Each Third Financing Unit consists of one (1) common share and one half of one (1/2) common share purchase warrant (each a “Third Financing Warrant”). Each whole Third Financing Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of $3.00 per share for a period of thirty-six (36) months from the closing date of the Third Financing. The Company paid a cash finder’s fee of $16,223 in connection with this Third Financing, as well as 7,545 finder’s warrants (the “Third Financing Finder’s Warrants”). Each Third Financing Finder’s Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of $2.15 per share for a period of sixty (60) months from the closing date of the Third Financing.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

SHARE BASED PAYMENTS

6 Months Ended

Sep. 30, 2015

SHARE BASED PAYMENTS [Text Block]

7. SHARE BASED PAYMENTS

(a) Stock options

The Company has a stock option plan whereby the Company is authorized to grant up to 12,108,016 options. Vesting and the term of an option is determined at the discretion of the Board of Directors of the Company.

The continuity of stock options for the periods as at September 30 and March 31, 2015, are as follows:

				Weighted
				Average		Aggregate
				Exercise Price		Intrinsic Value
	Number			(CAD)		(CAD)

Balance outstanding at March 31, 2015	4,920,000		$	1.14	$	10,120,000
Exercised	(94,640	)	$	0.60		-
Granted	50,000			0.98		-

Balance outstanding at September 30, 2015	4,875,360		$	1.15	$	-

Balance exercisable at September 30, 2015	3,272,862		$	1.15	$	-

The options outstanding and exercisable at September 30, 2015 are as follows:

		Options
		outstanding
		remaining					Number of
Number of		contractual life		Exercise		Grant date fair	options
options	Expiry date	(years)		Price (CAD)		value (CAD)	exercisable

3,520,000	June 18, 2019	3.72	$	0.60	$	0.23	2,346,667
155,360	June 20, 2019	3.72	$	0.60	$	0.23	92,860
100,000	July 14, 2017	1.79	$	2.52	$	1.06	100,000
450,000	December 8, 2019	4.19	$	2.92	$	1.65	450,000
100,000	December 8, 2019	4.19	$	2.92	$	1.49	33,334
400,000	December 8, 2019	4.19	$	2.96	$	1.56	200,000
100,000	March 16, 2020	4.46	$	3.20	$	1.61	33,334
50,000	August 15, 2015	4.88	$	0.98	$	0.45	16,667
4,875,360							3,272,862

The fair value of stock options vested during the periods ended September 30, 2015 and September 30, 2014 were estimated using the Black-Scholes option pricing model with the following weighted average assumptions:

	September 30, 2015	September 30, 2014
Stock price	$0.872	$0.55
Exercise Price	$1.105	$0.65
Expected life	4.1 years	4.1 years
Expected volatility	67.85%	115.73%
Risk – free interest rate	1.05%	1.46%
Dividend rate	0.00%	0.00%

The Company has adopted the simplified method prescribed by the SEC in SAB Topic 14 in respect of estimating the expected term of its stock options as its limited share purchase option history does not provide a reasonable basis to estimate the expected terms. Expected volatility was determined by reference to the average volatility rates of other companies in the same industry due to the Company’s limited trading history.

Non-Employee Stock Options

In accordance with the guidance of ASC 815-40-15, stock options awarded to non-employees that are performing services for Neuro are required to be accounted for as derivative liabilities once the services have been performed and the options have vested because they are considered not to be indexed to the Company’s stock due to their exercise price being denominated in a currency other than Neuro’s functional currency. Stock options awarded to non-employees that are not vested are accounted for as equity awards until the terms associated with their vesting requirements have been met.

The non-employee stock options are accounted for at their respective fair values and are summarized as follows for the six months ended September 30, 2015 and 2014:

	Six months ended September 30, 2015 $	Six months ended September 30, 2014 $
Fair value of non-employee options, beginning of the period	1,581,444	-
Issuance	-	121,344
Reallocation of vested non-employee options	690,885	7,419
Change in fair value of non-employee stock options during the period	( 1,910,420)	594,254

Fair value of non-employee options, end of the period	361,909	723,017

The non-employee options are required to be re-valued with the change in fair value of the liability recorded as a gain or loss on the change of fair value of derivative liability and included in other items in the Company’s Consolidated Statements of Loss at the end of each reporting period. The fair value of the options will continue to be classified as a liability until such time as they are exercised, expire or there is an amendment to the respective agreements that renders these financial instruments to be no longer classified as a liability.

Share-based payments are classified in the Company’s Statement of Loss as follows for the period ended September 30, 2015 and 2014:

	September 30, 2015 $	September 30, 2014 $

Consulting fees	( 8,899)	161,931
Research and development	( 257,481)	338,657
Wages and salaries	366,898	436,809

	100,518	937,397

(b) Share Purchase Warrants

During the three months ended September 30, 2015, the Company issued an aggregate of 70,423 common stock purchase warrants that are required to be accounted for as liabilities pursuant to ASC 815 because they are considered not to be indexed to the Company’s stock due to their exercise price being denominated in a currency other than the Company’s functional currency.

Pursuant to the guidance of ASC 815, warrants having an exercise price denominated in a currency other than the functional currency of the Company are required to be accounted for as liabilities are accounted for at their respective fair values, with the change in fair value recorded on the consolidated statement of operations as other income.

The warrants having an exercise price denominated in a currency other than the functional currency of the Company that are required to be accounted for as liabilities are summarized as follows for the periods ended September 30, 2015 and 2014:

	Six months ended September 30, 2015 $	Six months ended September 30, 2014 $

Fair value of warrants, beginning of the period	-	-
Issuance	532,523	-
Change in fair value of warrants during the period	( 496,669)	-

Fair value of warrants, end of the period	35,854	-

The fair value of the warrants issued during the periods ended September 30, 2015 and 2014 were estimated using the Black-Scholes pricing model with the following weighted average assumptions:

	September 30, 2015	September 30, 2014
Stock price	$0.61	-
Exercise Price	$2.15 - $3.00	-
Expected life	2.58 – 4.80 years	-
Expected volatility	67.85%	-
Risk – free interest rate	0.92% and 1.37%	-
Dividend rate	0.00%	-

The warrants are required to be re-valued with the change in fair value of the liability recorded as a gain or loss on the change of fair value of derivative liability and included in other items in the Company’s Consolidated Statements of Loss at the end of each reporting period. The fair value of the warrants will continue to be classified as a liability until such time as they are exercised, expire or there is an amendment to the respective agreements that renders these financial instruments to be no longer classified as a liability.

The Company closed its First Financing at $2.15 per First Financing Unit of 849,273 First Financing Units raising $1,825,937 on April 30, 2015. Each First Financing Unit consists of one common stock of the Company and one half of a First Financing Warrant of the Company where one full First Financing Warrant is exercisable for 3 years at $3.00 into one common share. The Company also issued 27,396 First Financing Finder’s Warrants. Each First Financing Finder’s Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of $3.00 per share for a period of thirty-six (36) months from the closing date of the First Financing.

The Company closed its Second Financing at $2.15 per Second Financing Unit of 335,463 Second Financing Units raising $721,243 on June 26, 2015. Each Second Financing Units consists of one common stock of the Company and one half of a Second Financing Warrant of the Company where one full Second Financing Warrant is exercisable for 3 years at $3.00 into one common share. The Company also issued 18,978 Second Financing Finder’s Warrants. Each Second Financing Finder’s Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of $2.15 per share for a period of sixty (60) months from the closing date of the Second Financing.

The Company closed its Third Financing at $2.15 per Third Financing Unit of 125,756 Third Financing Units raising $270,375 on July 17, 2015. Each Third Financing Units consists of one common stock of the Company and one half of a Third Financing Warrant of the Company where one full Third Financing Warrant is exercisable for 3 years at $3.00 into one common share. The Company also issued 7,545 Third Financing Finder’s Warrants. Each Third Financing Finder’s Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of $2.15 per share for a period of sixty (60) months from the closing date of the Third Financing.

The continuity of warrants for the six months ended September 30, 2015 is as follows:

	Number of warrants				Weighted Average Exercise Price
	CAD		US		CAD $	US $
Balance, March 31, 2015	8,444,400		-	$	1.00	-
Granted	-		709,164	$	-	2.97
Exercised	(14,400	)	-	$	1.00	-
Balance, September 30, 2015	8,430,000		709,164	$	1.00	2.97

The warrants outstanding and exercisable at September 30, 2015 are as follows:

Number of warrants outstanding	Exercise Price	Expiry Date
8,430,000	CAD $1.00	May 30, 2016
452,032	US $3.00	April 30, 2018
167,731	US $3.00	June 26, 2018
18,978	US $2.15	June 26, 2020
62,878	US $3.00	July 17, 2018
7,545	US $2.15	July 17, 2020

COMMITMENTS AND CONTINGENCIES

6 Months Ended

Sep. 30, 2015

COMMITMENTS AND CONTINGENCIES [Text Block]

8. COMMITMENTS AND CONTINGENCIES

(a)	The Company entered into a license agreement with Advanced NeuroRehabilitation, LLC (“ANR”) for an exclusive right on ANR’s patent pending technology, claims and knowhow. In addition to the issuance of 16,035,026 shares, the Company agreed to pay a 4% royalty on net revenue on the sales of devices covered by the patent-pending technology and services related to the therapy or use of devices covered by the patent-pending technology.

(b)	On March 7, 2014, the Company entered into a commercial development-to-supply program with Ximedica where Ximedica will design, develop and produce PoNS product solution suitable for clinical trial and commercial sale. Under the program, the Company is responsible for ensuring the device is in compliance with relevant laws and regulations. The agreed budget for phase 1B of development is $499,000 ; phase 2 is $1,065,000 ; Phase 3 and 4 is $1,389,000 and 2 ^nd software development cycle is $586,000, of which $4,147,423 was expensed as research and development since inception to September 30, 2015. Invoices are to be issued monthly for work in progress. The Company can cancel the project at any time with a written notice at least 30 days prior to the intended date of cancellation. As of September 30, 2015, the Company recorded a prepaid expense of $300,000 to Ximedica which will be applied at the end of the project. During the period ended September 30, 2015, the Company incurred charges of $797,425 (September 30, 2014 - $1,544,291) pursuant to this agreement.

(c)	On January 27, 2015 we received a demand letter containing allegations that we had entered into a consulting arrangement with the complainants and breached certain of its terms, and used certain intellectual property in the form of business and marketing plans allegedly prepared by the complainants, and seeking damages. On May 7, 2015, Mr. Rainer Maas and Dr. Jochen Scheld filed a complaint in the U.S. District Court for the Eastern District of Pennsylvania seeking monetary damages. Document discovery ends on October 23, 2015, a settlement conference with the magistrate judge is scheduled for December 2, 2015, discovery ends on February 26, 2016, and trial is scheduled for April 8, 2016. Management estimates that the contingent liability of such claim to be immaterial.

RELATED PARTY TRANSACTIONS

6 Months Ended

Sep. 30, 2015

RELATED PARTY TRANSACTIONS [Text Block]

9. RELATED PARTY TRANSACTIONS

For the period ended September 30, 2015, the Company was a party to the following related party transactions:

During the period ended September 30, 2015, the Company paid $49,560 (September 30, 2014 - $6,050) in consulting fees to directors of the Company.

During the period ended September 30, 2015, the Company paid $59,175 (September 30, 2014 - $34,418) to a company acting as the Company’s corporate advisor and employing its former Chief Financial Officer.

During the period ended September 30, 2015, $(257,481) (September 30, 2014 - $288,354) was included in research & development expenses as the fair value of stock-based compensation attributed to the options granted to two directors and one advisor for services rendered as non-employee consultants with respect to the design and development of the PoNS ^TM ; device.

During the period ended September 30, 2015, $366,898 (September 30, 2014 - $436,809) was included in wages & salaries expenses as the fair value of stock-based compensation attributed to options granted to three directors.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

SUBSEQUENT EVENTS

6 Months Ended

Sep. 30, 2015

SUBSEQUENT EVENTS [Text Block]

10. SUBSEQUENT EVENTS

On October 13, 2015, the Company announced that it entered into strategic agreements with A&B Company Limited (“A&B”) for the development and commercialization of the Portable Neuromodulation Stimulator (“PoNS™”) Therapy in China, Hong Kong, Macao, Taiwan and Singapore (the “Territories”). The agreement, a sale and licensing transaction, transfers ownership of certain patents, patent applications, and product support material for the PoNS ^TM device in the Territories to A&B. A&B assumes all development, patent (both application and defense), future manufacturing, clinical trial, and regulatory approval costs for the Territories. Helius and A&B will share and transfer ownership of any intellectual property or support material (developed by either party) for their respective geographies.

As consideration for the transfer of the intellectual property, the Company will receive:

	-	a per unit handling fee relating to the amount paid by A&B for any PoNS ^TM devices and relevant components purchased by A&B from NHC, an affiliate of Helius, or its designated manufacturer for the licensed territories, if any.
	-	Helius would also be entitled to a one-time milestone payment if a certain sales milestone within the Territories is reached.

A&B will provide a US$7.0 million funding commitment to Helius. The first US$2.0 million of this commitment has been drawn down and Helius will issue a convertible promissory note. As agreed, Helius will repay the US $2.0 million note through the issuance of approximately 2,083,333 shares of Helius’s common stock at a price of US $0.96 per share and approximately 1,041,667 3 -year warrants with an exercise price of US $1.44. Helius issued the shares of common stock and the warrants to A&B on November 10, 2015. The Company can elect to draw down the remaining US $5.0 million in the commitment within six months through issuing additional shares and warrants at a price based on the volume weighted average closing price of the Company’s shares of common stock. The funding commitment contains certain customary events of default, and may be cancelled or withdrawn if there is a material obstacle with regards to the PoNS ^TM obtaining eventual regulatory approval in the United States. Helius intends to, but is not obliged to, draw against the remainder of the funding commitment within the next six months to fund the continued development of the PoNS ^TM device.

b)	On October 21, 2015, the Company issued 750,000 options to an officer of the Company. The options are exercisable at CAD $0.87 for 5 years from the grant date. One-quarter of these options vested immediately, and the remaining options vest at a rate of 25% every year.

c)	On October 28, 2015, the Company issued 950,000 options to consultants and officers of the Company. The options are exercisable at CAD $0.84 for 5 years from the grant date. 614,000 options vest immediately, and the remaining 336,000 options vest at a rate of 14% every 6 months.

CORRECTION OF AN ERROR IN PREVIOUSLY ISSUED FINANCIAL STATEMENTS

6 Months Ended

Sep. 30, 2015

CORRECTION OF AN ERROR IN PREVIOUSLY ISSUED FINANCIAL STATEMENTS [Text Block]

11. CORRECTION OF AN ERROR IN PREVIOUSLY ISSUED FINANCIAL STATEMENTS

The Company’s previously issued financial statements have been restated to reflect the correction of an error in the re-measurement of non-employee stock option awards that had yet to vest.

Previously, the Company had recorded the stock-based compensation for the period ended September 30, 2015 based on the fair value of the awards on their respective grant dates. Under the provisions of ASC 505-50, the Company is required to measure stock-based compensation for non-employees at the earlier of the performance commitment date or the date that the services have been completed. A performance commitment date exists only when the counterparty has sufficient disincentive not to complete. Otherwise, the Company is required to re-measure unvested non-employee options at their respective fair values until the services have been completed or once the options have vested. Under the terms of the Company’s stock option awards to non-employees, there were no performance disincentives. As a result the Company is required to re-measure its non-employee awards until they have vested.

The correction of the error is presented in the Company’s interim condensed consolidated financial statements for the period ended September 30, 2015 as follows:

	Three months ended September 30, 2015
	As Originally Reported	Adjustment	As Restated
Consulting fees	$20,199	$(45,191)	$(24,992)
Research and development	243,262	$(241,731)	$1,531
Wages and salaries	$223,349	$(48,998)	$174,351

Net income (loss) for the period	$1,039,361	$335,920	$1,375,281

Comprehensive income (loss) for the period	$475,078	$332,684	$807,762

Basic and diluted loss per share	$(0.02)	$-	$(0.02)

	Six months ended September 30, 2015
	As Originally Reported	Adjustment	As Restated
Consulting fees	$163,021	$(82,026)	$80,995
Research and development	1,629,938	$(257,481)	$1,372,457
Wages and salaries	$662,414	$4,364	$666,778
Change in fair value of derivative liability	$1,305,796	$583,850	$1,889,646

Net income (loss) for the period	$(2,055,493)	$918,993	$(1,136,500)

Comprehensive income (loss) for the period	$(2,582,386)	$918,993	$(1,663,393)

Basic and diluted loss per share	$(0.03)	$0.01	$(0.02)

	As at September 30, 2015
	As Originally Reported	Adjustment	As Restated
Additional paid-in capital	$1,819,735	$24,769	$1,844,504

Accumulated deficit	$(20,535,182)	$(24,769)	$(20,559,951)

The collection of the error is presented in the Company's interim condensed consolidated financial statements for the period ended September 30, 2014 as follows:

	Three months ended September 30, 2014
	As Originally Reported	Adjustment	As Restated
Consulting fees	$36,013	$179,017	$215,030
Research and development	$1,062,927	$191,259	$1,254,186
Wages and salaries	$295,017	$38,628	$333,645

Net income (loss) for the period	$(3,347,223)	$(408,904)	$(3,756,127)

Comprehensive income (loss) for the period	$(3,140,437)	$(408,904)	$(3,549,341)

Basic and diluted loss per share	$(0.05)	$(0.01)	$(0.06)

	Six months ended September 30, 2014
	As Originally Reported	Adjustment	As Restated
Consulting fees	$236,862	$29,491	$266,353
Research and development	$1,716,186	$288,354	$2,004,540
Wages and salaries	$465,998	$86,258	$552,256

Net loss for the period	$(4,915,977)	$(404,103)	$(5,320,080)

Comprehensive loss for the period	$(4,603,132)	$(404,103)	$(5,007,235)

Basic and diluted loss per share	$(0.10)	$-	$(0.10)

SECOND RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS

6 Months Ended

Sep. 30, 2015

SECOND RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS [Text Block]

12. SECOND RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS

The Company’s previously issued and restated financial statements have been restated to reflect the correction of an error in the classification of the warrants issued in the First Financing, the Second Financing, and the Third Financing.

Previously, the Company had recorded the First Financing Warrants, First Financing Finders Warrants, Second Financing Warrants, Second Financing Finders Warrants, Third Financing Warrants, and Third Financing Finders Warrants (collectively, the “Warrants”) as equity instruments. Under the provisions of ASC 815-40-15, if the exercise price of an instrument is denominated in a currency other than the Company’s functional currency, the instrument shall not be considered as indexed to the Company’s own stock because it is exposed to fluctuations in foreign currency exchange rates. Instead, the instrument should be recorded as a liability at fair value through profit or loss. The functional currency of the Company is the Canadian dollar but the exercise prices of the Warrants are denominated in U.S. dollars, so under ASC 815-40-15,, the Warrants must be classified as liabilities at fair value through profit or loss. As a result, the Company is required to reclassify the fair value of the Warrants from equity to liability through profit or loss.

The correction of the error is presented in the Company’s interim condensed consolidated financial statements for the period ended September 30, 2015 as follows:

	Three months ended September 30, 2015
	As reported after first restatement	Adjustment	As Restated
Change in fair value of derivative liability	$1,484,174	$410,131	$1,894,305

Net income (loss) for the period	$1,375,281	$410,131	$1,785,412

Comprehensive income (loss) for the period	$807,762	$410,131	$1,217,893

Basic gain (loss) per share	$0.02	$0.01	$0.03

Diluted gain (loss) per share	$0.02	$0.01	$0.03

	Six months ended September 30, 2015
	As reported after first restatement	Adjustment	As Restated
Change in fair value of derivative liability	$1,889,646	$517,443	$2,407,089

Net income (loss) for the period	$(1,136,500)	$517,443	$(619,057)

Comprehensive income (loss) for the period	$(1,663,393)	$517,443	$(1,145,950)

Basic gain (loss) per share	$(0.02)	$0.01	$(0.01)

Diluted gain (loss) per share	$(0.02)	$0.01	$(0.01)

	As at September 30, 2015
	As reported after first restatement	Adjustment	As Restated
Derivative liability	$361,909	$35,854	$397,763
Common stock	$19,109,428	$(532,523)	$18,576,905
Additional paid-in capital	$1,844,504	$(20,774)	$1,823,730

Accumulated deficit	$(20,559,951)	$517,443	$(20,042,508)

There was no effect on cash flow for each of the periods and therefore there has been no restatement to the consolidated statements of cash flows.

- Definition

The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6510796

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22583-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22580-107794

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22499-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=51655806&loc=d3e765-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=51655806&loc=d3e725-108305

+ Details

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Sep. 30, 2015

Basis of Presentation and Liquidity [Policy Text Block]

Basis of Presentation and Liquidity

Fair Value of Financial Assets and Liabilities [Policy Text Block]

Fair Value of Financial Assets and Liabilities

Level 1 – Quoted prices in active markets for identical assets or liabilities;

Level 2 – Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable; and

Cash and cash equivalents and short-term investment are measured using Level 1 inputs.

A summary of the Company’s Level 3 liabilities for the periods ended September 30, 2015 and 2014 are as follows:

Non-Employee Options

	Six months ended		Six months ended
	Sept 30, 2015		Sept 30, 2014
	$		$
Beginning fair value	1,581,444		-
Issuance of non-employee options	-		121,344
Reallocation of vested non-employee options	690,885		7,419
Change in fair value	(1,910,420	)	594,254
Ending fair value of non-employee options	361,909		723,017

Warrants

Beginning fair value	-		-
Issuance of warrants	532,523		-
Change in fair value	(496,669	)	-
Ending fair value of warrants	35,854		-
Ending fair value of Level 3 liability	397,763		-

Basic and Diluted Income (Loss) per Share

The basic and diluted earnings per share for the three and six months ended September 30, 2015 and 2014 were calculated as follows:

		Three months ended					Six months ended
		September 30, 2015		September 30, 2014			September 30, 2015			September 30, 2014
Basic
Numerator
Net income (loss)	$	1,785,412	$	(3,756,127	)	$	(619,057	)	$	(5,320,080	)
Denominator
Weighted average common shares outstanding		64,408,500		63,104,788			64,055,508			51,025,119

Basic net income (loss) per share	$	0.03	$	(0.06	)	$	(0.01	)	$	(0.10	)

Diluted
Numerator
Net income (loss) for diluted income per share	$	1,785,412	$	(3,756,127	)	$	(619,057	)	$	(5,320,080	)
Denominator
Weighted average common shares outstanding		64,408,500		63,104,788			64,055,508			51,025,119
Potential share
issuances
Common share options		2,135,104		2,855,914			2,652,859			2,814,267

Common share warrants		2,577,769		5,031,974			4,483,136			5,002,389
Weighted average number of common shares outstanding used in computing diluted earnings per share		66,543,604		65,960,702			71,191,503			58,841,775

Diluted earnings per share	$	0.03	$	(0.06	)	$	(0.01	)	$	(0.10	)

Recent Accounting Pronouncements [Policy Text Block]

Recent Accounting Pronouncements

SIGNIFICANT ACCOUNTING POLICIES (Tables)

6 Months Ended

Sep. 30, 2015

Fair Value, by Balance Sheet Grouping [Table Text Block]

	Six months ended		Six months ended
	Sept 30, 2015		Sept 30, 2014
	$		$
Beginning fair value	1,581,444		-
Issuance of non-employee options	-		121,344
Reallocation of vested non-employee options	690,885		7,419
Change in fair value	(1,910,420	)	594,254
Ending fair value of non-employee options	361,909		723,017

Schedule of Fair Value of Warrants [Table Text Block]

Beginning fair value	-		-
Issuance of warrants	532,523		-
Change in fair value	(496,669	)	-
Ending fair value of warrants	35,854		-
Ending fair value of Level 3 liability	397,763		-

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

		Three months ended					Six months ended
		September 30, 2015		September 30, 2014			September 30, 2015			September 30, 2014
Basic
Numerator
Net income (loss)	$	1,785,412	$	(3,756,127	)	$	(619,057	)	$	(5,320,080	)
Denominator
Weighted average common shares outstanding		64,408,500		63,104,788			64,055,508			51,025,119

Basic net income (loss) per share	$	0.03	$	(0.06	)	$	(0.01	)	$	(0.10	)

Diluted
Numerator
Net income (loss) for diluted income per share	$	1,785,412	$	(3,756,127	)	$	(619,057	)	$	(5,320,080	)
Denominator
Weighted average common shares outstanding		64,408,500		63,104,788			64,055,508			51,025,119
Potential share
issuances
Common share options		2,135,104		2,855,914			2,652,859			2,814,267

Common share warrants		2,577,769		5,031,974			4,483,136			5,002,389
Weighted average number of common shares outstanding used in computing diluted earnings per share		66,543,604		65,960,702			71,191,503			58,841,775

Diluted earnings per share	$	0.03	$	(0.06	)	$	(0.01	)	$	(0.10	)

SHARE BASED PAYMENTS (Tables)

6 Months Ended

Sep. 30, 2015

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

				Weighted
				Average		Aggregate
				Exercise Price		Intrinsic Value
	Number			(CAD)		(CAD)

Balance outstanding at March 31, 2015	4,920,000		$	1.14	$	10,120,000
Exercised	(94,640	)	$	0.60		-
Granted	50,000			0.98		-

Balance outstanding at September 30, 2015	4,875,360		$	1.15	$	-

Balance exercisable at September 30, 2015	3,272,862		$	1.15	$	-

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]

		Options
		outstanding
		remaining					Number of
Number of		contractual life		Exercise		Grant date fair	options
options	Expiry date	(years)		Price (CAD)		value (CAD)	exercisable

3,520,000	June 18, 2019	3.72	$	0.60	$	0.23	2,346,667
155,360	June 20, 2019	3.72	$	0.60	$	0.23	92,860
100,000	July 14, 2017	1.79	$	2.52	$	1.06	100,000
450,000	December 8, 2019	4.19	$	2.92	$	1.65	450,000
100,000	December 8, 2019	4.19	$	2.92	$	1.49	33,334
400,000	December 8, 2019	4.19	$	2.96	$	1.56	200,000
100,000	March 16, 2020	4.46	$	3.20	$	1.61	33,334
50,000	August 15, 2015	4.88	$	0.98	$	0.45	16,667
4,875,360							3,272,862

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	September 30, 2015	September 30, 2014
Stock price	$0.872	$0.55
Exercise Price	$1.105	$0.65
Expected life	4.1 years	4.1 years
Expected volatility	67.85%	115.73%
Risk – free interest rate	1.05%	1.46%
Dividend rate	0.00%	0.00%

Schedule of Non-Employee Share-based Compensation Arrangements Fair Values [Table Text Block]

	Six months ended September 30, 2015 $	Six months ended September 30, 2014 $
Fair value of non-employee options, beginning of the period	1,581,444	-
Issuance	-	121,344
Reallocation of vested non-employee options	690,885	7,419
Change in fair value of non-employee stock options during the period	( 1,910,420)	594,254

Fair value of non-employee options, end of the period	361,909	723,017

Share-Based Payments Classified in the Companys Statement of Loss [Table Text Block]

	September 30, 2015 $	September 30, 2014 $

Consulting fees	( 8,899)	161,931
Research and development	( 257,481)	338,657
Wages and salaries	366,898	436,809

	100,518	937,397

Schedule of Warrants, Fair Values [Table Text Block]

	Six months ended September 30, 2015 $	Six months ended September 30, 2014 $

Fair value of warrants, beginning of the period	-	-
Issuance	532,523	-
Change in fair value of warrants during the period	( 496,669)	-

Fair value of warrants, end of the period	35,854	-

Schedule of Share-based Payment Award, Warrants, Valuation Assumptions [Table Text Block]

	September 30, 2015	September 30, 2014
Stock price	$0.61	-
Exercise Price	$2.15 - $3.00	-
Expected life	2.58 – 4.80 years	-
Expected volatility	67.85%	-
Risk – free interest rate	0.92% and 1.37%	-
Dividend rate	0.00%	-

Schedule of Stockholder's Equity Note Warrants Or Rights Activity [Table Text Block]

	Number of warrants				Weighted Average Exercise Price
	CAD		US		CAD $	US $
Balance, March 31, 2015	8,444,400		-	$	1.00	-
Granted	-		709,164	$	-	2.97
Exercised	(14,400	)	-	$	1.00	-
Balance, September 30, 2015	8,430,000		709,164	$	1.00	2.97

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

Number of warrants outstanding	Exercise Price	Expiry Date
8,430,000	CAD $1.00	May 30, 2016
452,032	US $3.00	April 30, 2018
167,731	US $3.00	June 26, 2018
18,978	US $2.15	June 26, 2020
62,878	US $3.00	July 17, 2018
7,545	US $2.15	July 17, 2020

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

CORRECTION OF AN ERROR IN PREVIOUSLY ISSUED FINANCIAL STATEMENTS (Tables)

3 Months Ended

6 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Schedule of Error Corrections and Prior Period Adjustments in Statement of Operations [Table Text Block]

	Three months ended September 30, 2015
	As Originally Reported	Adjustment	As Restated
Consulting fees	$20,199	$(45,191)	$(24,992)
Research and development	243,262	$(241,731)	$1,531
Wages and salaries	$223,349	$(48,998)	$174,351

Net income (loss) for the period	$1,039,361	$335,920	$1,375,281

Comprehensive income (loss) for the period	$475,078	$332,684	$807,762

Basic and diluted loss per share	$(0.02)	$-	$(0.02)

	Three months ended September 30, 2014
	As Originally Reported	Adjustment	As Restated
Consulting fees	$36,013	$179,017	$215,030
Research and development	$1,062,927	$191,259	$1,254,186
Wages and salaries	$295,017	$38,628	$333,645

Net income (loss) for the period	$(3,347,223)	$(408,904)	$(3,756,127)

Comprehensive income (loss) for the period	$(3,140,437)	$(408,904)	$(3,549,341)

Basic and diluted loss per share	$(0.05)	$(0.01)	$(0.06)

	Six months ended September 30, 2015
	As Originally Reported	Adjustment	As Restated
Consulting fees	$163,021	$(82,026)	$80,995
Research and development	1,629,938	$(257,481)	$1,372,457
Wages and salaries	$662,414	$4,364	$666,778
Change in fair value of derivative liability	$1,305,796	$583,850	$1,889,646

Net income (loss) for the period	$(2,055,493)	$918,993	$(1,136,500)

Comprehensive income (loss) for the period	$(2,582,386)	$918,993	$(1,663,393)

Basic and diluted loss per share	$(0.03)	$0.01	$(0.02)

	Six months ended September 30, 2014
	As Originally Reported	Adjustment	As Restated
Consulting fees	$236,862	$29,491	$266,353
Research and development	$1,716,186	$288,354	$2,004,540
Wages and salaries	$465,998	$86,258	$552,256

Net loss for the period	$(4,915,977)	$(404,103)	$(5,320,080)

Comprehensive loss for the period	$(4,603,132)	$(404,103)	$(5,007,235)

Basic and diluted loss per share	$(0.10)	$-	$(0.10)

Schedule of Error Corrections and Prior Period Adjustments in Consolidated Balance Sheet [Table Text Block]

	As at September 30, 2015
	As Originally Reported	Adjustment	As Restated
Additional paid-in capital	$1,819,735	$24,769	$1,844,504

Accumulated deficit	$(20,535,182)	$(24,769)	$(20,559,951)

SECOND RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS (Tables)

3 Months Ended

6 Months Ended

Sep. 30, 2015

Schedule Of Error Corrections And Prior Period AdjustmentsIn Condensed Consolidated Financial Statements [Table Text Block]

	Three months ended September 30, 2015
	As reported after first restatement	Adjustment	As Restated
Change in fair value of derivative liability	$1,484,174	$410,131	$1,894,305

Net income (loss) for the period	$1,375,281	$410,131	$1,785,412

Comprehensive income (loss) for the period	$807,762	$410,131	$1,217,893

Basic gain (loss) per share	$0.02	$0.01	$0.03

Diluted gain (loss) per share	$0.02	$0.01	$0.03

	Six months ended September 30, 2015
	As reported after first restatement	Adjustment	As Restated
Change in fair value of derivative liability	$1,889,646	$517,443	$2,407,089

Net income (loss) for the period	$(1,136,500)	$517,443	$(619,057)

Comprehensive income (loss) for the period	$(1,663,393)	$517,443	$(1,145,950)

Basic gain (loss) per share	$(0.02)	$0.01	$(0.01)

Diluted gain (loss) per share	$(0.02)	$0.01	$(0.01)

Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]

	As at September 30, 2015
	As reported after first restatement	Adjustment	As Restated
Derivative liability	$361,909	$35,854	$397,763
Common stock	$19,109,428	$(532,523)	$18,576,905
Additional paid-in capital	$1,844,504	$(20,774)	$1,823,730

Accumulated deficit	$(20,559,951)	$517,443	$(20,042,508)

SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)	6 Months Ended
SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)	Sep. 30, 2015 USD ($)
Significant Accounting Policies 1	$ 619,057
Significant Accounting Policies 2	20,042,508
Significant Accounting Policies 3	19,423,451
Significant Accounting Policies 4	192,256
Significant Accounting Policies 5	$ 418,893
Significant Accounting Policies 6	5,877,500
Significant Accounting Policies 7	9,130,000
Significant Accounting Policies 8	835
Significant Accounting Policies 9	30

CONVERTIBLE DEBENTURE (Narrative) (Details)	6 Months Ended
CONVERTIBLE DEBENTURE (Narrative) (Details)	Sep. 30, 2015 USD ($)
Convertible Debenture 1	8.00%
Convertible Debenture 2	$ 1,000,100
Convertible Debenture 3	85.00%
Convertible Debenture 4	$ 176,488

PROMISSORY NOTE (Narrative) (Details)	6 Months Ended
PROMISSORY NOTE (Narrative) (Details)	Sep. 30, 2015 USD ($) shares
Promissory Note 1 \| $	$ 200,000
Promissory Note 2	6.00%
Promissory Note 3	30,000
Promissory Note 4	30,000
Promissory Note 5	30,000

DEFERRED EXPENSE REIMBURSEMENT (Narrative) (Details)	6 Months Ended
DEFERRED EXPENSE REIMBURSEMENT (Narrative) (Details)	Sep. 30, 2015 USD ($)
Deferred Expense Reimbursement 1	$ 1,037,089
Deferred Expense Reimbursement 2	916,972
Deferred Expense Reimbursement 3	$ 120,847

COMMON STOCK (Narrative) (Details)	6 Months Ended
COMMON STOCK (Narrative) (Details)	Sep. 30, 2015 USD ($) $ / shares shares
Common Stock 1	$ 1,825,937
Common Stock 2 \| shares	849,273
Common Stock 3	$ 2.15
Common Stock 4 \| $ / shares	$ 3.00
Common Stock 5	$ 84,074
Common Stock 6	27,396
Common Stock 7 \| $ / shares	$ 3.00
Common Stock 8	$ 721,243
Common Stock 9 \| shares	335,463
Common Stock 10	$ 2.15
Common Stock 11 \| $ / shares	$ 3.00
Common Stock 12	$ 40,803
Common Stock 13	18,978
Common Stock 14 \| $ / shares	$ 2.15
Common Stock 15	$ 270,375
Common Stock 16 \| shares	125,756
Common Stock 17	$ 2.15
Common Stock 18 \| $ / shares	$ 3.00
Common Stock 19	$ 16,223
Common Stock 20	7,545
Common Stock 21 \| $ / shares	$ 2.15

SHARE BASED PAYMENTS (Narrative) (Details)	6 Months Ended
SHARE BASED PAYMENTS (Narrative) (Details)	Sep. 30, 2015 USD ($) yr $ / shares shares
Share Based Payments 1 \| shares	12,108,016
Share Based Payments 2	70,423
Share Based Payments 3	$ 2.15
Share Based Payments 4	849,273
Share Based Payments 5	$ 1,825,937
Share Based Payments 6 \| yr	3
Share Based Payments 7	$ 3.00
Share Based Payments 8	27,396
Share Based Payments 9 \| $ / shares	$ 3.00
Share Based Payments 10	$ 2.15
Share Based Payments 11	335,463
Share Based Payments 12	$ 721,243
Share Based Payments 13 \| yr	3
Share Based Payments 14	$ 3.00
Share Based Payments 15	18,978
Share Based Payments 16 \| $ / shares	$ 2.15
Share Based Payments 17	$ 2.15
Share Based Payments 18	125,756
Share Based Payments 19	$ 270,375
Share Based Payments 20 \| yr	3
Share Based Payments 21	$ 3.00
Share Based Payments 22	7,545
Share Based Payments 23 \| $ / shares	$ 2.15

COMMITMENTS AND CONTINGENCIES (Narrative) (Details)	6 Months Ended
COMMITMENTS AND CONTINGENCIES (Narrative) (Details)	Sep. 30, 2015 USD ($) d shares
Commitments And Contingencies 1 \| shares	16,035,026
Commitments And Contingencies 2	4.00%
Commitments And Contingencies 3	$ 499,000
Commitments And Contingencies 4	2
Commitments And Contingencies 5	$ 1,065,000
Commitments And Contingencies 6	$ 1,389,000
Commitments And Contingencies 7	2
Commitments And Contingencies 8	$ 586,000
Commitments And Contingencies 9	$ 4,147,423
Commitments And Contingencies 10 \| d	30
Commitments And Contingencies 11	$ 300,000
Commitments And Contingencies 12	797,425
Commitments And Contingencies 13	$ 1,544,291

RELATED PARTY TRANSACTIONS (Narrative) (Details)	6 Months Ended
RELATED PARTY TRANSACTIONS (Narrative) (Details)	Sep. 30, 2015 USD ($)
Related Party Transactions 1	$ 49,560
Related Party Transactions 2	6,050
Related Party Transactions 3	59,175
Related Party Transactions 4	34,418
Related Party Transactions 5	(257,481)
Related Party Transactions 6	288,354
Related Party Transactions 7	366,898
Related Party Transactions 8	$ 436,809

SUBSEQUENT EVENTS (Narrative) (Details) - 6 months ended Sep. 30, 2015	USD ($) yr mo $ / shares shares	CAD ($) yr mo shares
Subsequent Events 1	$ 7,000,000
Subsequent Events 2	2,000,000
Subsequent Events 3	$ 2,000,000
Subsequent Events 4 \| shares	2,083,333	2,083,333
Subsequent Events 5 \| $ / shares	$ 0.96
Subsequent Events 6	1,041,667	1,041,667
Subsequent Events 7	3	3
Subsequent Events 8	$ 1.44
Subsequent Events 9	$ 5,000,000
Subsequent Events 10 \| shares	750,000	750,000
Subsequent Events 11		$ 0.87
Subsequent Events 12 \| yr	5	5
Subsequent Events 13	25.00%	25.00%
Subsequent Events 14 \| shares	950,000	950,000
Subsequent Events 15		$ 0.84
Subsequent Events 16 \| yr	5	5
Subsequent Events 17 \| shares	614,000	614,000
Subsequent Events 18 \| shares	336,000	336,000
Subsequent Events 19	14.00%	14.00%
Subsequent Events 20 \| mo	6	6

Fair Value, by Balance Sheet Grouping (Details)	6 Months Ended
Fair Value, by Balance Sheet Grouping (Details)	Sep. 30, 2015 USD ($) shares
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 1	$ 1,581,444
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 2 \| shares	0
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 3	$ 0
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 4	121,344
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 5	690,885
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 6	7,419
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 7	(1,910,420)
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 8	594,254
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 9	361,909
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 10	$ 723,017

Schedule of Fair Value of Warrants (Details)	6 Months Ended
Schedule of Fair Value of Warrants (Details)	Sep. 30, 2015 USD ($)
Significant Accounting Policies Schedule Of Fair Value Of Warrants 1	$ 0
Significant Accounting Policies Schedule Of Fair Value Of Warrants 2	0
Significant Accounting Policies Schedule Of Fair Value Of Warrants 3	532,523
Significant Accounting Policies Schedule Of Fair Value Of Warrants 4	0
Significant Accounting Policies Schedule Of Fair Value Of Warrants 5	(496,669)
Significant Accounting Policies Schedule Of Fair Value Of Warrants 6	0
Significant Accounting Policies Schedule Of Fair Value Of Warrants 7	35,854
Significant Accounting Policies Schedule Of Fair Value Of Warrants 8	0
Significant Accounting Policies Schedule Of Fair Value Of Warrants 9	397,763
Significant Accounting Policies Schedule Of Fair Value Of Warrants 10	$ 0

Schedule of Earnings Per Share, Basic and Diluted (Details)	6 Months Ended
	Sep. 30, 2015 USD ($)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 1	$ 1,785,412
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 2	(3,756,127)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 3	(619,057)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 4	(5,320,080)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 5	64,408,500
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 6	63,104,788
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 7	64,055,508
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 8	$ 51,025,119
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 9	0.03
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 10	(0.06)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 11	(0.01)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 12	(0.10)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 13	$ 1,785,412
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 14	(3,756,127)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 15	(619,057)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 16	(5,320,080)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 17	64,408,500
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 18	63,104,788
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 19	64,055,508
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 20	51,025,119
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 21	2,135,104
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 22	2,855,914
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 23	2,652,859
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 24	2,814,267
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 25	2,577,769
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 26	5,031,974
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 27	4,483,136
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 28	5,002,389
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 29	66,543,604
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 30	65,960,702
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 31	71,191,503
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 32	$ 58,841,775
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 33	0.03
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 34	(0.06)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 35	(0.01)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 36	(0.10)

Schedule of Share-based Compensation, Stock Options, Activity (Details)	6 Months Ended
	Sep. 30, 2015 USD ($)
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 1	$ 4,920,000
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 2	1.14
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 3	$ 10,120,000
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 4	$ (94,640)
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 5	0.60
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 6	$ 0
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 7	$ 50,000
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 8	0.98
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 9	$ 0
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 10	$ 4,875,360
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 11	1.15
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 12	$ 0
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 13	$ 3,272,862
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 14	1.15
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 15	$ 0

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award (Details)	6 Months Ended
	Sep. 30, 2015 USD ($)
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 1	$ 3,520,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 2	3.72
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 3	0.60
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 4	0.23
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 5	$ 2,346,667
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 6	$ 155,360
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 7	3.72
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 8	0.60
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 9	0.23
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 10	$ 92,860
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 11	$ 100,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 12	1.79
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 13	2.52
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 14	1.06
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 15	$ 100,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 16	$ 450,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 17	4.19
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 18	2.92
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 19	1.65
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 20	$ 450,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 21	$ 100,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 22	4.19
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 23	2.92
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 24	1.49
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 25	$ 33,334
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 26	$ 400,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 27	4.19
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 28	2.96
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 29	1.56
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 30	$ 200,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 31	$ 100,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 32	4.46
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 33	3.20
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 34	1.61
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 35	$ 33,334
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 36	$ 50,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 37	4.88
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 38	0.98
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 39	0.45
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 40	$ 16,667
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 41	4,875,360
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 42	$ 3,272,862

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)	6 Months Ended
	Sep. 30, 2015 USD ($) yr
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 1	$ 0.872
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 2	0.55
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 3	1.105
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 4	$ 0.65
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 5 \| yr	4.1
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 6 \| yr	4.1
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 7	67.85%
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 8	115.73%
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 9	1.05%
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 10	1.46%
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 11	0.00%
Share Based Payments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 12	0.00%

Schedule of Non-Employee Share-based Compensation Arrangements Fair Values (Details)	6 Months Ended
	Sep. 30, 2015 USD ($)
Share Based Payments Schedule Of Non-employee Share-based Compensation Arrangements Fair Values 1	$ 1,581,444
Share Based Payments Schedule Of Non-employee Share-based Compensation Arrangements Fair Values 2	0
Share Based Payments Schedule Of Non-employee Share-based Compensation Arrangements Fair Values 3	0
Share Based Payments Schedule Of Non-employee Share-based Compensation Arrangements Fair Values 4	121,344
Share Based Payments Schedule Of Non-employee Share-based Compensation Arrangements Fair Values 5	690,885
Share Based Payments Schedule Of Non-employee Share-based Compensation Arrangements Fair Values 6	7,419
Share Based Payments Schedule Of Non-employee Share-based Compensation Arrangements Fair Values 7	1,910,420
Share Based Payments Schedule Of Non-employee Share-based Compensation Arrangements Fair Values 8	594,254
Share Based Payments Schedule Of Non-employee Share-based Compensation Arrangements Fair Values 9	361,909
Share Based Payments Schedule Of Non-employee Share-based Compensation Arrangements Fair Values 10	$ 723,017

Share-Based Payments Classified in the Companys Statement of Loss (Details)	6 Months Ended
	Sep. 30, 2015 USD ($)
Share Based Payments Share-based Payments Classified In The Companys Statement Of Loss 1	$ 8,899
Share Based Payments Share-based Payments Classified In The Companys Statement Of Loss 2	161,931
Share Based Payments Share-based Payments Classified In The Companys Statement Of Loss 3	257,481
Share Based Payments Share-based Payments Classified In The Companys Statement Of Loss 4	338,657
Share Based Payments Share-based Payments Classified In The Companys Statement Of Loss 5	366,898
Share Based Payments Share-based Payments Classified In The Companys Statement Of Loss 6	436,809
Share Based Payments Share-based Payments Classified In The Companys Statement Of Loss 7	100,518
Share Based Payments Share-based Payments Classified In The Companys Statement Of Loss 8	$ 937,397

Schedule of Warrants, Fair Values (Details)	6 Months Ended
Schedule of Warrants, Fair Values (Details)	Sep. 30, 2015 USD ($)
Share Based Payments Schedule Of Warrants, Fair Values 1	$ 0
Share Based Payments Schedule Of Warrants, Fair Values 2	0
Share Based Payments Schedule Of Warrants, Fair Values 3	532,523
Share Based Payments Schedule Of Warrants, Fair Values 4	0
Share Based Payments Schedule Of Warrants, Fair Values 5	496,669
Share Based Payments Schedule Of Warrants, Fair Values 6	0
Share Based Payments Schedule Of Warrants, Fair Values 7	35,854
Share Based Payments Schedule Of Warrants, Fair Values 8	$ 0

Schedule of Share-based Payment Award, Warrants, Valuation Assumptions (Details)	6 Months Ended
	Sep. 30, 2015 USD ($) yr
Share Based Payments Schedule Of Share-based Payment Award, Warrants, Valuation Assumptions 1	$ 0.61
Share Based Payments Schedule Of Share-based Payment Award, Warrants, Valuation Assumptions 2	0
Share Based Payments Schedule Of Share-based Payment Award, Warrants, Valuation Assumptions 3	2.15
Share Based Payments Schedule Of Share-based Payment Award, Warrants, Valuation Assumptions 4	3.00
Share Based Payments Schedule Of Share-based Payment Award, Warrants, Valuation Assumptions 5	$ 0
Share Based Payments Schedule Of Share-based Payment Award, Warrants, Valuation Assumptions 6	2.58
Share Based Payments Schedule Of Share-based Payment Award, Warrants, Valuation Assumptions 7 \| yr	4.8
Share Based Payments Schedule Of Share-based Payment Award, Warrants, Valuation Assumptions 8	$ 0
Share Based Payments Schedule Of Share-based Payment Award, Warrants, Valuation Assumptions 9	67.85%
Share Based Payments Schedule Of Share-based Payment Award, Warrants, Valuation Assumptions 10	$ 0
Share Based Payments Schedule Of Share-based Payment Award, Warrants, Valuation Assumptions 11	0.92%
Share Based Payments Schedule Of Share-based Payment Award, Warrants, Valuation Assumptions 12	1.37%
Share Based Payments Schedule Of Share-based Payment Award, Warrants, Valuation Assumptions 13	$ 0
Share Based Payments Schedule Of Share-based Payment Award, Warrants, Valuation Assumptions 14	0.00%
Share Based Payments Schedule Of Share-based Payment Award, Warrants, Valuation Assumptions 15	$ 0

Schedule of Stockholder's Equity Note Warrants Or Rights Activity (Details)	6 Months Ended
	Sep. 30, 2015 USD ($)
Share Based Payments Schedule Of Stockholder's Equity Note Warrants Or Rights Activity 1	$ 8,444,400
Share Based Payments Schedule Of Stockholder's Equity Note Warrants Or Rights Activity 2	$ 0
Share Based Payments Schedule Of Stockholder's Equity Note Warrants Or Rights Activity 3	1.00
Share Based Payments Schedule Of Stockholder's Equity Note Warrants Or Rights Activity 4	$ 0
Share Based Payments Schedule Of Stockholder's Equity Note Warrants Or Rights Activity 5	0
Share Based Payments Schedule Of Stockholder's Equity Note Warrants Or Rights Activity 6	709,164
Share Based Payments Schedule Of Stockholder's Equity Note Warrants Or Rights Activity 7	$ 0
Share Based Payments Schedule Of Stockholder's Equity Note Warrants Or Rights Activity 8	2.97
Share Based Payments Schedule Of Stockholder's Equity Note Warrants Or Rights Activity 9	$ (14,400)
Share Based Payments Schedule Of Stockholder's Equity Note Warrants Or Rights Activity 10	$ 0
Share Based Payments Schedule Of Stockholder's Equity Note Warrants Or Rights Activity 11	1.00
Share Based Payments Schedule Of Stockholder's Equity Note Warrants Or Rights Activity 12	$ 0
Share Based Payments Schedule Of Stockholder's Equity Note Warrants Or Rights Activity 13	8,430,000
Share Based Payments Schedule Of Stockholder's Equity Note Warrants Or Rights Activity 14	$ 709,164
Share Based Payments Schedule Of Stockholder's Equity Note Warrants Or Rights Activity 15	1.00
Share Based Payments Schedule Of Stockholder's Equity Note Warrants Or Rights Activity 16	2.97

Schedule of Stockholders' Equity Note, Warrants or Rights (Details) - 6 months ended Sep. 30, 2015	USD ($)	CAD ($)
Share Based Payments Schedule Of Stockholders' Equity Note, Warrants Or Rights 1	$ 8,430,000
Share Based Payments Schedule Of Stockholders' Equity Note, Warrants Or Rights 2		$ 1.00
Share Based Payments Schedule Of Stockholders' Equity Note, Warrants Or Rights 3	452,032
Share Based Payments Schedule Of Stockholders' Equity Note, Warrants Or Rights 4	3.00
Share Based Payments Schedule Of Stockholders' Equity Note, Warrants Or Rights 5	167,731
Share Based Payments Schedule Of Stockholders' Equity Note, Warrants Or Rights 6	3.00
Share Based Payments Schedule Of Stockholders' Equity Note, Warrants Or Rights 7	18,978
Share Based Payments Schedule Of Stockholders' Equity Note, Warrants Or Rights 8	2.15
Share Based Payments Schedule Of Stockholders' Equity Note, Warrants Or Rights 9	62,878
Share Based Payments Schedule Of Stockholders' Equity Note, Warrants Or Rights 10	3.00
Share Based Payments Schedule Of Stockholders' Equity Note, Warrants Or Rights 11	7,545
Share Based Payments Schedule Of Stockholders' Equity Note, Warrants Or Rights 12	$ 2.15

Schedule of Error Corrections and Prior Period Adjustments in Statement of Operations (Details) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 1	$ 20,199
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 2	(45,191)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 3	(24,992)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 4	243,262
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 5	(241,731)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 6	1,531
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 7	223,349
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 8	(48,998)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 9	174,351
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 10	1,039,361
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 11	335,920
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 12	1,375,281
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 13	475,078
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 14	332,684
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 15	807,762
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 16	(0.02)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 17	0
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 18	$ (0.02)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 1			$ 163,021
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 2			(82,026)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 3			80,995
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 4			1,629,938
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 5			(257,481)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 6			1,372,457
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 7			662,414
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 8			4,364
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 9			666,778
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 10			1,305,796
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 11			583,850
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 12			1,889,646
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 13			(2,055,493)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 14			918,993
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 15			(1,136,500)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 16			(2,582,386)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 17			918,993
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 18			(1,663,393)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 19			(0.03)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 20			0.01
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 21			$ (0.02)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 1		$ 36,013
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 2		179,017
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 3		215,030
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 4		1,062,927
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 5		191,259
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 6		1,254,186
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 7		295,017
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 8		38,628
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 9		333,645
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 10		(3,347,223)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 11		(408,904)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 12		(3,756,127)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 13		(3,140,437)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 14		(408,904)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 15		(3,549,341)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 16		(0.05)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 17		(0.01)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 18		$ (0.06)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 1				$ 236,862
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 2				29,491
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 3				266,353
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 4				1,716,186
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 5				288,354
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 6				2,004,540
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 7				465,998
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 8				86,258
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 9				552,256
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 10				(4,915,977)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 11				(404,103)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 12				(5,320,080)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 13				(4,603,132)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 14				(404,103)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 15				(5,007,235)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 16				(0.10)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 17				0
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations 18				$ (0.10)

Schedule of Error Corrections and Prior Period Adjustments in Consolidated Balance Sheet (Details)	6 Months Ended
	Sep. 30, 2015 USD ($)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheet 1	$ 1,819,735
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheet 2	24,769
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheet 3	1,844,504
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheet 4	(20,535,182)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheet 5	(24,769)
Correction Of An Error In Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheet 6	$ (20,559,951)

Schedule Of Error Corrections And Prior Period AdjustmentsIn Condensed Consolidated Financial Statements (Details) - USD ($)	3 Months Ended	6 Months Ended
	Sep. 30, 2015	Sep. 30, 2015
Second Restatement Of Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustmentsin Condensed Consolidated Financial Statements 1	$ 1,484,174
Second Restatement Of Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustmentsin Condensed Consolidated Financial Statements 2	410,131
Second Restatement Of Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustmentsin Condensed Consolidated Financial Statements 3	1,894,305
Second Restatement Of Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustmentsin Condensed Consolidated Financial Statements 4	1,375,281
Second Restatement Of Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustmentsin Condensed Consolidated Financial Statements 5	410,131
Second Restatement Of Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustmentsin Condensed Consolidated Financial Statements 6	1,785,412
Second Restatement Of Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustmentsin Condensed Consolidated Financial Statements 7	807,762
Second Restatement Of Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustmentsin Condensed Consolidated Financial Statements 8	410,131
Second Restatement Of Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustmentsin Condensed Consolidated Financial Statements 9	1,217,893
Second Restatement Of Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustmentsin Condensed Consolidated Financial Statements 10	0.02
Second Restatement Of Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustmentsin Condensed Consolidated Financial Statements 11	0.01
Second Restatement Of Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustmentsin Condensed Consolidated Financial Statements 12	0.03
Second Restatement Of Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustmentsin Condensed Consolidated Financial Statements 13	0.02
Second Restatement Of Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustmentsin Condensed Consolidated Financial Statements 14	0.01
Second Restatement Of Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustmentsin Condensed Consolidated Financial Statements 15	$ 0.03
Second Restatement Of Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustmentsin Condensed Consolidated Financial Statements 1		$ 1,889,646
Second Restatement Of Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustmentsin Condensed Consolidated Financial Statements 2		517,443
Second Restatement Of Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustmentsin Condensed Consolidated Financial Statements 3		2,407,089
Second Restatement Of Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustmentsin Condensed Consolidated Financial Statements 4		(1,136,500)
Second Restatement Of Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustmentsin Condensed Consolidated Financial Statements 5		517,443
Second Restatement Of Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustmentsin Condensed Consolidated Financial Statements 6		(619,057)
Second Restatement Of Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustmentsin Condensed Consolidated Financial Statements 7		(1,663,393)
Second Restatement Of Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustmentsin Condensed Consolidated Financial Statements 8		517,443
Second Restatement Of Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustmentsin Condensed Consolidated Financial Statements 9		(1,145,950)
Second Restatement Of Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustmentsin Condensed Consolidated Financial Statements 10		(0.02)
Second Restatement Of Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustmentsin Condensed Consolidated Financial Statements 11		0.01
Second Restatement Of Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustmentsin Condensed Consolidated Financial Statements 12		(0.01)
Second Restatement Of Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustmentsin Condensed Consolidated Financial Statements 13		(0.02)
Second Restatement Of Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustmentsin Condensed Consolidated Financial Statements 14		0.01
Second Restatement Of Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustmentsin Condensed Consolidated Financial Statements 15		$ (0.01)

Schedule of Error Corrections and Prior Period Adjustments (Details)	6 Months Ended
	Sep. 30, 2015 USD ($)
Second Restatement Of Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments 1	$ 361,909
Second Restatement Of Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments 2	35,854
Second Restatement Of Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments 3	397,763
Second Restatement Of Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments 4	19,109,428
Second Restatement Of Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments 5	(532,523)
Second Restatement Of Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments 6	18,576,905
Second Restatement Of Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments 7	1,844,504
Second Restatement Of Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments 8	(20,774)
Second Restatement Of Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments 9	1,823,730
Second Restatement Of Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments 10	(20,559,951)
Second Restatement Of Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments 11	517,443
Second Restatement Of Previously Issued Financial Statements Schedule Of Error Corrections And Prior Period Adjustments 12	$ (20,042,508)